PROJECT DETAILS
Therapeutic Area
Mental Health / PTSD
Population
Veterans
Publication
Brenner et al. 2022
Capabilities
PRO Research, Clinical Trials, Regulatory Strategy
Clinical Research
PRO Innovation
Mental Health
Leveraging Patient-Reported Outcomes for PTSD Treatment Innovation
A Phase IIa RCT demonstrating how validated PRO measures combined with biomarkers can enhance clinical validation, regulatory credibility, and patient-centric drug development in mental health therapeutics.
🧠
PRO-Biomarker Integration
Pub.
Peer-Reviewed
hs-CRP
Biomarker Correlation
6
PRO Instruments
50%
Treatment Gap Addressed
the challenge
Addressing a Critical Gap in PTSD Treatment
Current PTSD treatments, including cognitive behavioral therapy (CBT) and SSRIs, have approximately a 50% non-response rate leaving a significant gap in effective, patient-centered solutions for veterans and other trauma survivors.
Regulatory hurdles further complicated the development of novel treatments. Many patient-reported outcome measures lacked validation against biological markers like high-sensitivity C-reactive protein (hs-CRP), making it challenging to demonstrate the clinical significance of patient-reported improvements.
"Traditional interventions often fail to integrate patient-reported experiences with biological markers, limiting their real-world applicability and regulatory credibility."
Our Approach
Integrating PROs with Biomarker Evidence
This Phase IIa randomized controlled trial evaluated Lactobacillus rhamnosus GG (LGG) as adjunct treatment for PTSD in Veterans. The study was designed to demonstrate how PROs can enhance clinical validation when properly integrated with biomarker evidence.
01
Comprehensive PRO Battery
Leveraged validated instruments including CAPS-5 and PCL-5 for PTSD severity, PHQ-9 for depression, PSQI and ISI for sleep quality, and mIGT for cognitive function.
02
Biomarker Integration
Correlated PRO improvements with plasma hs-CRP reductions, creating a biological validation pathway for patient-reported symptom changes.
03
Longitudinal Tracking
Collected self-reported mental health data over time to demonstrate treatment trajectory and sustained improvements.
04
Regulatory Alignment
Designed the study to enhance regulatory credibility by linking patient-reported outcomes with objective biological evidence.
"
Integrating PROs with biomarker-driven approaches enhances regulatory credibility, market positioning, and patient-centric innovation in mental health therapeutics.
Study Conclusion
the results
PRO-Biomarker Correlation Demonstrated
The study showed clear alignment between patient-reported improvements and biological evidence, strengthening the case for PRO-integrated drug development in mental health.
📄
Published
Peer-reviewed findings contributing to evidence base
📊
Aligned
PRO reductions correlated with hs-CRP biomarker changes
📈
Higher
Adherence and engagement vs. standard approaches
key insights
Implications for Drug Development
1
PROs Strengthen Regulatory Submissions
When validated against biomarkers, patient-reported outcomes provide compelling evidence for regulatory review and approval decisions.
2
Biological Validation Matters
Correlating subjective improvements with objective biomarker changes addresses skepticism about PRO reliability in mental health trials.
3
Patient Engagement Improves
Comprehensive PRO assessment increases patient engagement and adherence, improving both data quality and treatment outcomes.
4
Market Positioning Enhanced
Published PRO-biomarker correlation data strengthens value messaging with payers and provides differentiation in competitive markets.
Building PRO Evidence Strategy?
Let's discuss how to integrate patient-reported outcomes into your development program for regulatory and commercial success.